Cargando…

Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ

This work investigated whether the anti-resorptive drugs (ARDs) zoledronic acid (Zol) and denosumab (Dmab) affect differently the levels of circulating immune cell subsets, possibly predicting the risk of developing medication-related ONJ (MRONJ) during the first 18 months of treatment. Blood sample...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roato, Ilaria, Pavone, Lorenzo, Pedraza, Riccardo, Bosso, Ilaria, Baima, Giacomo, Erovigni, Francesco, Mussano, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605172/ https://www.ncbi.nlm.nih.gov/pubmed/37887274 http://dx.doi.org/10.3390/cells12202430

Ejemplares similares

Senescent Markers Expressed by Periodontal Ligament-Derived Stem Cells (PDLSCs) Harvested from Patients with Periodontitis Can Be Rejuvenated by RG108
por: Roato, Ilaria, et al.
Publicado: (2023)

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
por: Limones, Alvaro, et al.
Publicado: (2020)

Osteogenic Differentiation Modulates the Cytokine, Chemokine, and Growth Factor Profile of ASCs and SHED
por: Mussano, Federico, et al.
Publicado: (2018)

Oral Cavity as a Source of Mesenchymal Stem Cells Useful for Regenerative Medicine in Dentistry
por: Roato, Ilaria, et al.
Publicado: (2021)

Challenges of Periodontal Tissue Engineering: Increasing Biomimicry through 3D Printing and Controlled Dynamic Environment
por: Roato, Ilaria, et al.
Publicado: (2022)

Advances on Bone Substitutes through 3D Bioprinting
por: Genova, Tullio, et al.
Publicado: (2020)

Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw
por: Roato, Ilaria, et al.
Publicado: (2023)

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
por: Raje, N, et al.
Publicado: (2016)

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis
por: Campisi, Giuseppina, et al.
Publicado: (2021)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)

The Crosstalk Between Osteodifferentiating Stem Cells and Endothelial Cells Promotes Angiogenesis and Bone Formation
por: Genova, Tullio, et al.
Publicado: (2019)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
por: Yassin, Mohamed A., et al.
Publicado: (2020)

Biohybrid Bovine Bone Matrix for Controlled Release of Mesenchymal Stem/Stromal Cell Lyosecretome: A Device for Bone Regeneration
por: Bari, Elia, et al.
Publicado: (2021)

A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy
por: Fusco, Vittorio, et al.
Publicado: (2021)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
por: Kadaru, Tarun, et al.
Publicado: (2021)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

MRONJ and COVID-19 caution
por: Hasan, A., et al.
Publicado: (2021)

Cancer Stem Cells, Bone and Tumor Microenvironment: Key Players in Bone Metastases
por: Roato, Ilaria, et al.
Publicado: (2018)

Zoledronate/Anti-VEGF Neutralizing Antibody Combination Administration Increases Osteal Macrophages in a Murine Model of MRONJ Stage 0-like Lesions
por: Kaneko, Haruka, et al.
Publicado: (2023)

Adipose-Derived Stromal Vascular Fraction/Xenohybrid Bone Scaffold: An Alternative Source for Bone Regeneration
por: Roato, Ilaria, et al.
Publicado: (2018)

CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche
por: Bertolini, Giulia, et al.
Publicado: (2022)

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020)

Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
por: Makras, Polyzois, et al.
Publicado: (2021)

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

Isolation and Characterization of Buccal Fat Pad and Dental Pulp MSCs from the Same Donor
por: Genova, Tullio, et al.
Publicado: (2021)

Mechanical and Biological Characterization of PMMA/Al(2)O(3) Composites for Dental Implant Abutments
por: Roato, Ilaria, et al.
Publicado: (2023)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset
por: Marcianò, Antonia, et al.
Publicado: (2021)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
por: Fusco, Vittorio, et al.
Publicado: (2018)

Endothelial Cells Promote Osteogenesis by Establishing a Functional and Metabolic Coupling With Human Mesenchymal Stem Cells
por: Petrillo, Sara, et al.
Publicado: (2022)

Bone Impairment in Phenylketonuria Is Characterized by Circulating Osteoclast Precursors and Activated T Cell Increase
por: Roato, Ilaria, et al.
Publicado: (2010)

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension
por: Ramchand, Sabashini K., et al.
Publicado: (2022)

Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_05015ejbhh0l2dag76rhqrf3gf